Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093283 | 0.91 | NLRP3 (0.60) | NLRP3ALDH1A1HPGDKDM4EPDK1 | |
| SCHEMBL9819481 | 0.84 | KMT2A (0.62) | ALDH1A1HPGDKDM4EPDK1PDK2 | |
| SCHEMBL3790491 | 0.83 | LCK (0.52) | NLRP3ALDH1A1CXCL8PDK1PDK2 | |
| SCHEMBL3788964 | 0.83 | ALDH1A1 (0.75) | NLRP3ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL513878 | 0.83 | MEN1 (0.58) | ALDH1A1HPGDKDM4EPDK1PDK2 | |
| SCHEMBL3780963 | 0.83 | KMT2A (0.56) | ALDH1A1HPGDKDM4EMAPTMEN1 | |
| SCHEMBL2091197 | 0.82 | ALDH1A1 (0.73) | ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL3783627 | 0.81 | GPR35 (0.57) | ALDH1A1HPGDKDM4EPDK1PDK2 | |
| SCHEMBL2093882 | 0.81 | RAF1 (0.53) | ALDH1A1HPGDKDM4EMAPTMEN1 | |
| SCHEMBL1023162 | 0.80 | HPGD (0.50) | NLRP3ALDH1A1HPGDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | NLRP3 1774/4885ALDH1A1 4339/4885HPGD 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.